{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:03:46Z","timestamp":1788444226250,"version":"build-2803163510"},"reference-count":45,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Insulin resistance and elevated endothelin-1 (ET-1) levels are key contributors to cardiovascular and renal complications in patients with type 2 diabetes mellitus (T2DM) and hypertension. This study compared the effects of telmisartan with other commonly used antihypertensive agents on insulin sensitivity in terms of homeostatic model assessment for insulin resistance (HOMA-IR) and vascular endothelial function in terms of ET-1 levels in patients with T2DM and hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomised, open-label study, 182 patients with coexisting T2DM and hypertension were screened between May 2023 and September 2024. The study was registered with the Clinical Trials Registry\u2013India (CTRI; CTRI\/2023\/04\/051878). Seventy eligible patients were enrolled and randomised 1:1 to receive telmisartan (n=34) or other antihypertensive agents (amlodipine, n=22; cilnidipine, n=12; ramipril, n=2; total n=36) for 12 weeks. The primary outcome was the change in insulin sensitivity as measured by the HOMA-IR. ET-1 levels were evaluated as a secondary outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, the median HOMA-IR values were 4.1 [interquartile range (IQR): 2.2\u20135.9] in the telmisartan group and 3.9 (IQR: 3.1\u20135.9) in the comparator group. After 12 weeks, the median HOMA-IR significantly decreased in the telmisartan group to 1.79 (IQR: 1.30\u20132.63) compared to 3.45 (IQR: 2.43\u20135.12) in the other antihypertensive group (\n                      <jats:italic>P<\/jats:italic>\n                      =0.001). Baseline ET-1 levels were 19.23 pg\/mL (IQR: 10.8\u201329.9) and 17.1 pg\/mL (IQR: 10.3\u201326.48) in the telmisartan and comparator groups, respectively. At 12 weeks, median ET-1 levels decreased to 12.49 pg\/mL (IQR: 5.70\u201318.70) and 11.22 pg\/mL (IQR:4.84\u201323.20), respectively (\n                      <jats:italic>P<\/jats:italic>\n                      =0.90).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation and conclusions<\/jats:title>\n                    <jats:p>Telmisartan significantly improved insulin sensitivity at 12 weeks compared to other antihypertensive agents in patients with T2DM and hypertension. However, the reduction in ET-1 levels was similar across groups, suggesting a comparable effect on endothelial function over 12 weeks. These findings suggest that, beyond its antihypertensive action, telmisartan may offer favourable metabolic benefits that could help limit diabetes-related micro- and macrovascular complications compared with other commonly prescribed antihypertensives.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.25259\/ijmr_1859_2025","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T16:26:05Z","timestamp":1772382365000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Telmisartan\n                    <i>vs.<\/i>\n                    other antihypertensives on cardiometabolic and vascular outcomes in diabetic hypertension: A randomised trial"],"prefix":"10.25259","volume":"163","author":[{"given":"Simi Bridjit","family":"Gomaz","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimple Jeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Mohandas","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Ambwani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaykaran","family":"Charan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of General Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmveer","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"10.25259\/IJMR_1859_2025\/ref-1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct Target Ther."},{"key":"10.25259\/IJMR_1859_2025\/ref-2","doi-asserted-by":"publisher","first-page":"18892","DOI":"10.1038\/s41598-024-69062-7","article-title":"Hypertension among persons with type 2 diabetes and its related demographic, socioeconomic and lifestyle factors in the Fasa cohort study","volume":"14","author":"Taheri","year":"2024","journal-title":"Sci Rep."},{"key":"10.25259\/IJMR_1859_2025\/ref-3","doi-asserted-by":"publisher","first-page":"103758","DOI":"10.1016\/j.amsu.2022.103758","article-title":"Prevalence of hypertension in type\u20132 diabetes mellitus","volume":"78","author":"Naseri","year":"2022","journal-title":"Ann Med Surg (Lond)."},{"key":"10.25259\/IJMR_1859_2025\/ref-4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cen.14607","article-title":"Sleep, circadian rhythms, and type 2 diabetes mellitus","volume":"96","author":"Parameswaran","year":"2022","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.25259\/IJMR_1859_2025\/ref-5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.5114\/aoms.2015.52350","article-title":"Central obesity, type 2 diabetes and insulin: Exploring a pathway full of thorns","volume":"11","author":"Papaetis","year":"2015","journal-title":"Arch Med Sci."},{"key":"10.25259\/IJMR_1859_2025\/ref-6","doi-asserted-by":"publisher","first-page":"e13086","DOI":"10.1111\/obr.13086","article-title":"Endothelin\u20131 in the pathophysiology of obesity and insulin resistance","volume":"21","author":"Jenkins","year":"2020","journal-title":"Obes Rev."},{"key":"10.25259\/IJMR_1859_2025\/ref-7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s43152-024-00056-3","article-title":"Cellular and molecular mechanisms of insulin resistance","volume":"5","author":"Chandrasekaran","year":"2024","journal-title":"Curr Tissue Microenviron Rep."},{"key":"10.25259\/IJMR_1859_2025\/ref-8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/pathophysiology28040031","article-title":"Circulating Levels of Endothelin-1 and Big Endothelin-1 in Patients with Essential Hypertension","volume":"28","author":"Kostov","year":"2021","journal-title":"Pathophysiology."},{"key":"10.25259\/IJMR_1859_2025\/ref-9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: Insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther."},{"key":"10.25259\/IJMR_1859_2025\/ref-10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fphys.2018.00382","article-title":"Cardiac remodeling: Endothelial cells have more to say than just no","volume":"9","author":"Segers","year":"2018","journal-title":"Front Physiol."},{"key":"10.25259\/IJMR_1859_2025\/ref-11","doi-asserted-by":"publisher","first-page":"807548","DOI":"10.3389\/fphar.2021.807548","article-title":"Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales","volume":"12","author":"Dahl\u00e9n","year":"2022","journal-title":"Front Pharmacol."},{"key":"10.25259\/IJMR_1859_2025\/ref-12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12978-021-01207-7","article-title":"Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: A network meta\u2013analysis","volume":"18","author":"Zhao","year":"2021","journal-title":"Reprod Health."},{"key":"10.25259\/IJMR_1859_2025\/ref-13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/ijms23031264","article-title":"Metformin and insulin resistance: A review of the underlying mechanisms behind changes in GLUT4\u2013mediated glucose transport","volume":"23","author":"Herman","year":"2022","journal-title":"Int J Mol Sci."},{"key":"10.25259\/IJMR_1859_2025\/ref-14","doi-asserted-by":"publisher","first-page":"e14249","DOI":"10.1097\/MD.0000000000014249","article-title":"The effects of metformin on insulin resistance in overweight or obese children and adolescents: A PRISMA\u2013compliant systematic review and meta\u2013analysis of randomized controlled trials","volume":"98","author":"Sun","year":"2019","journal-title":"Medicine (Baltimore)."},{"key":"10.25259\/IJMR_1859_2025\/ref-15","doi-asserted-by":"publisher","first-page":"e39445","DOI":"10.7759\/cureus.39445","article-title":"A Systematic review and meta\u2013analysis of randomized controlled trials comparing the effects of biguanides (Metformin) and thiazolidinediones on glucose tolerance and insulin sensitivity in patients with type ii diabetes mellitus","volume":"15","author":"Zaki","year":"2023","journal-title":"Cureus."},{"key":"10.25259\/IJMR_1859_2025\/ref-17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.63623\/sr9fb890","article-title":"Polypharmacy in type 2 diabetes mellitus and related conditions: A double\u2013edged sword: A narrative review","volume":"2","author":"Cakir","year":"2025","journal-title":"Adv Clin Pharmacol Ther."},{"key":"10.25259\/IJMR_1859_2025\/ref-18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/medicina55080436","article-title":"Polypharmacy in type 2 diabetes mellitus: insights from an internal medicine department","volume":"55","author":"Dobric\u0103","year":"2019","journal-title":"Medicina (Kaunas)."},{"key":"10.25259\/IJMR_1859_2025\/ref-19","doi-asserted-by":"crossref","DOI":"10.1186\/s43094-024-00655-9","article-title":"Expanding telmisartan\u2019s therapeutic horizon: Exploring its multifaceted mechanisms beyond cardiovascular disorders","volume":"10","author":"Ahire","year":"2024","journal-title":"Futur J Pharm Sci."},{"key":"10.25259\/IJMR_1859_2025\/ref-20","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.2147\/DMSO.S265399","article-title":"Anti\u2013diabetic effect of telmisartan through its partial PPAR\u03b3\u2013agonistic activity","volume":"13","author":"Ayza","year":"2020","journal-title":"Diabetes Metab Syndr Obes."},{"key":"10.25259\/IJMR_1859_2025\/ref-21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12933-016-0430-5","article-title":"Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor \u03b4 (PPAR\u03b4): From bedside to bench","volume":"15","author":"Chang","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"10.25259\/IJMR_1859_2025\/ref-22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/03007995.2016.1176015","article-title":"Telmisartan: A multifaceted antihypertension drug","volume":"32","author":"Rizos","year":"2016","journal-title":"Curr Med Res Opin."},{"key":"10.25259\/IJMR_1859_2025\/ref-23","first-page":"481","article-title":"Effect of amlodipine on insulin resistance tumor necrosis factor\u2013alpha levels in hypertensive obese type 2 diabetic patients","volume":"120","author":"Ersoy","year":"2004","journal-title":"Indian J Med Res."},{"key":"10.25259\/IJMR_1859_2025\/ref-24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/DMSO.S49767","article-title":"Effect of calcium channel blockers on incidence of diabetes: A meta\u2013analysis","volume":"6","author":"Noto","year":"2013","journal-title":"Diabetes Metab Syndr Obes."},{"key":"10.25259\/IJMR_1859_2025\/ref-25","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1161\/ATVBAHA.112.300985","article-title":"Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival","volume":"33","author":"Siragusa","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.25259\/IJMR_1859_2025\/ref-26","doi-asserted-by":"publisher","first-page":"9771","DOI":"10.1038\/s41598-022-13772-3","article-title":"Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti\u2013vascular remodeling effects","volume":"12","author":"Tehrani","year":"2022","journal-title":"Sci Rep."},{"key":"10.25259\/IJMR_1859_2025\/ref-27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41440-018-0014-8","article-title":"Pleiotropic effects of calcium channel blockers","volume":"41","author":"Toyoda","year":"2018","journal-title":"Hypertens Res."},{"key":"10.25259\/IJMR_1859_2025\/ref-28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.diabres.2008.10.014","article-title":"Comparison of effects of amlodipine and angiotensin receptor blockers on the intima\u2013media thickness of carotid arterial wall (AAA study: Amlodipine vs ARB in atherosclerosis study)","volume":"83","author":"Ikeda","year":"2009","journal-title":"Diabetes Res Clin Pract."},{"key":"10.25259\/IJMR_1859_2025\/ref-29","doi-asserted-by":"publisher","first-page":"11242","DOI":"10.3390\/ijerph191811242","article-title":"Endothelial function assessment by flow\u2013mediated dilation method: A valuable tool in the evaluation of the cardiovascular system","volume":"19","author":"Mu\u0107ka","year":"2022","journal-title":"Int J Environ Res Public Health."},{"key":"10.25259\/IJMR_1859_2025\/ref-30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3892\/etm.2017.5451","article-title":"Effects of telmisartan on vascular endothelial function, inflammation and insulin resistance in patients with coronary heart disease and diabetes mellitus","volume":"15","author":"Chen","year":"2018","journal-title":"Exp Ther Med."},{"key":"10.25259\/IJMR_1859_2025\/ref-31","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.2174\/0929867325666180713144806","article-title":"Calcium channel blockers in restoration of endothelial function: Systematic review and meta\u2013analysis of randomized controlled trials","volume":"26","author":"Radenkovi\u0107","year":"2019","journal-title":"Curr Med Chem."},{"key":"10.25259\/IJMR_1859_2025\/ref-32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2710.2011.01295.x","article-title":"Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes","volume":"37","author":"Suksomboon","year":"2012","journal-title":"J Clin Pharm Ther."},{"key":"10.25259\/IJMR_1859_2025\/ref-33","doi-asserted-by":"publisher","first-page":"e0214727","DOI":"10.1371\/journal.pone.0214727","article-title":"Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open\u2013label, randomized clinical trial","volume":"14","author":"Naruse","year":"2019","journal-title":"PLoS One."},{"key":"10.25259\/IJMR_1859_2025\/ref-34","doi-asserted-by":"crossref","first-page":"zwac056.091.","DOI":"10.1093\/eurjpc\/zwac056.091","article-title":"Alternations in markers of insulin resistance: HOMA\u2013IR, HOMA\u2013B, QUICKI, after dual therapy combination with telmisartan\/amlodipine in prediabetic hypertensive patients","volume":"29","author":"Liontos","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"10.25259\/IJMR_1859_2025\/ref-35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1089\/dia.2009.0126","article-title":"Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment","volume":"12","author":"Fuke","year":"2010","journal-title":"Diabetes Technol Ther."},{"key":"10.25259\/IJMR_1859_2025\/ref-36","doi-asserted-by":"publisher","first-page":"6983","DOI":"10.1007\/s10787-025-01995-5","article-title":"Anti-inflammatory potential of telmisartan compared to other antihypertensives: secondary outcomes from a randomized trial","volume":"33","author":"Gomaz","year":"2025","journal-title":"Inflammopharmacology."},{"key":"10.25259\/IJMR_1859_2025\/ref-37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/hr.2010.107","article-title":"Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan","volume":"33","author":"Wago","year":"2010","journal-title":"Hypertens Res."},{"key":"10.25259\/IJMR_1859_2025\/ref-38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.diabres.2006.11.014","article-title":"Telmisartan reduced blood pressure and HOMA\u2013IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients","volume":"77","author":"Usui","year":"2007","journal-title":"Diabetes Res Clin Pract."},{"key":"10.25259\/IJMR_1859_2025\/ref-39","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.mayocp.2022.06.036","article-title":"Effect of the renin\u2013angiotensin system inhibitors on inflammatory markers: A systematic review and meta\u2013analysis of randomized controlled trials","volume":"97","author":"Awad","year":"2022","journal-title":"Mayo Clin Proc."},{"key":"10.25259\/IJMR_1859_2025\/ref-40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1475-2840-10-79","article-title":"Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT)","volume":"10","author":"Fukao","year":"2011","journal-title":"Cardiovasc Diabetol."},{"key":"10.25259\/IJMR_1859_2025\/ref-41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1024\/0301-1526\/a000971","article-title":"Effect of ACEI and ARB treatment on nitric oxide\u2013dependent endothelial function","volume":"50","author":"Li","year":"2021","journal-title":"Vasa."},{"key":"10.25259\/IJMR_1859_2025\/ref-42","doi-asserted-by":"publisher","first-page":"115325","DOI":"10.1016\/j.bcp.2022.115325","article-title":"Nitric oxide deficiency is a primary driver of hypertension","volume":"206","author":"Bryan","year":"2022","journal-title":"Biochem Pharmacol."},{"key":"10.25259\/IJMR_1859_2025\/ref-43","doi-asserted-by":"publisher","first-page":"116169","DOI":"10.1016\/j.biopha.2024.116169","article-title":"Effects of telmisartan on metabolic syndrome components: A comprehensive review","volume":"171","author":"Imenshahidi","year":"2024","journal-title":"Biomed Pharmacother."},{"key":"10.25259\/IJMR_1859_2025\/ref-44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1530\/JME-21-0239","article-title":"Telmisartan is the most effective ARB to increase adiponectin via PPAR\u03b1 in adipocytes","volume":"69","author":"Hattori","year":"2022","journal-title":"J Mol Endocrinol."},{"key":"10.25259\/IJMR_1859_2025\/ref-45","doi-asserted-by":"publisher","first-page":"3851718","DOI":"10.1155\/2019\/3851718","article-title":"Telmisartan attenuates uric acid\u2013induced epithelial\u2013mesenchymal transition in renal tubular cells","volume":"2019","author":"Zha","year":"2019","journal-title":"Biomed Res Int."},{"key":"10.25259\/IJMR_1859_2025\/ref-47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1742-2094-9-102","article-title":"Telmisartan directly ameliorates the neuronal inflammatory response to IL\u20131\u03b2 partly through the JNK\/c\u2013Jun and NADPH oxidase pathways","volume":"9","author":"Pang","year":"2012","journal-title":"J Neuroinflammation."}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/telmisartan-vs-other-antihypertensives-on-cardiometabolic-and-vascular-outcomes-in-diabetic-hypertension-a-randomised-trial\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/telmisartan-vs-other-antihypertensives-on-cardiometabolic-and-vascular-outcomes-in-diabetic-hypertension-a-randomised-trial\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:16:57Z","timestamp":1773303417000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/telmisartan-vs-other-antihypertensives-on-cardiometabolic-and-vascular-outcomes-in-diabetic-hypertension-a-randomised-trial\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":45,"alternative-id":["10.25259\/IJMR_1859_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_1859_2025","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"article-number":"41"}}